NASDAQ:EWTX Edgewise Therapeutics Q4 2024 Earnings Report $41.05 -3.46 (-7.77%) Closing price 04:00 PM EasternExtended Trading$41.02 -0.03 (-0.09%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Edgewise Therapeutics EPS ResultsActual EPS-$0.42Consensus EPS -$0.39Beat/MissMissed by -$0.03One Year Ago EPSN/AEdgewise Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEdgewise Therapeutics Announcement DetailsQuarterQ4 2024Date3/3/2025TimeBefore Market OpensConference Call DateMonday, March 3, 2025Conference Call Time8:00AM ETUpcoming EarningsEdgewise Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Edgewise Therapeutics Earnings HeadlinesEdgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 TranscriptSeptember 22 at 7:00 PM | seekingalpha.comEdgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - SlideshowSeptember 22 at 3:33 PM | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 23 at 1:00 AM | Stansberry Research (Ad)Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500September 22 at 7:00 AM | prnewswire.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 21 at 8:07 AM | americanbankingnews.comEdgewise Therapeutics Sees Unusually High Options Volume (NASDAQ:EWTX)September 20 at 1:21 AM | americanbankingnews.comSee More Edgewise Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email. Email Address About Edgewise TherapeuticsEdgewise Therapeutics (NASDAQ:EWTX) is a clinical-stage biotechnology company focused on developing small-molecule medicines for severe muscle disorders. The company’s research is centered on therapies intended to address the biological mechanisms that contribute to muscle damage and impaired function in diseases affecting skeletal and cardiac muscle. Edgewise’s lead program is sevasemten (also known as EDG-5506), an orally administered investigational therapy designed to reduce contraction-related muscle injury by selectively modulating fast skeletal muscle contractility. The program has been evaluated in clinical studies involving Duchenne muscular dystrophy and other muscular dystrophies, including Becker muscular dystrophy and certain limb-girdle muscular dystrophies. The company has also developed EDG-7500, an investigational cardiac myosin inhibitor intended for potential use in hypertrophic cardiomyopathy and other conditions involving abnormal cardiac muscle contraction. Edgewise was founded in 2017 and is headquartered in Boulder, Colorado. Its programs have been studied through clinical development activities involving patients and research sites in multiple regions. Kevin Koch, Ph.D., serves as president and chief executive officer.View Edgewise Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
